trending Market Intelligence /marketintelligence/en/news-insights/trending/_DXZzjbpa4jMaALLEqKNfw2 content esgSubNav
In This List

US judge may reject Novelion unit's deal with DOJ

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


US judge may reject Novelion unit's deal with DOJ

U.S. District Judge William Young may reject the plea agreement between Aegerion Pharmaceuticals Inc. and the U.S. Department of Justice, Reuters reported.

In September, the Novelion Therapeutics Inc. unit agreed to plead guilty to charges relating to its high-cholesterol drug Juxtapid and pay $36 million to resolve criminal and civil liability arising from the charges.

Young did not issue a definitive rejection of the plea agreement at a court hearing in Boston but noted that his instinct was to reject the deal, the news outlet reported.